Commercial Nanopore Sequencer Remains 'Top Goal' for Electronic BioSciences after Nanopatch Launch | GenomeWeb

Electronic BioSciences is developing an electronic nanopore sequencing platform that promises high speed and low per-run costs.

Late last year, the company launched a version of its hardware platform, called Nanopatch, for electrophysiology measurements while continuing to optimize alpha-hemolysin nanopores for DNA sequencing.

Developing a commercial electronic nanopore sequencing system remains the firm's "top goal," according to Eric Ervin, EBS' vice president of research and development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.